4
Participants
Start Date
January 27, 2025
Primary Completion Date
July 31, 2029
Study Completion Date
July 31, 2029
Obinutuzumab
Intravenous Infusion
ABBV-453
Oral; Tablet
Royal Prince Alfred Hospital /ID# 263129, Sydney
Austin Health /ID# 256776, Heidelberg
Gold coast University Hospital /ID# 255785, Southport
Royal Perth Hospital /ID# 256464, Perth
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 263433, Berlin
IRCCS Ospedale San Raffaele /ID# 263064, Milan
Universitaetsklinikum Hamburg-Eppendorf /ID# 263730, Hamburg
Universitaetsklinikum Schleswig-Holstein - Campus Kiel /ID# 263150, Kiel
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 263065, Bologna
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 264622, Billings
Yitzhak Shamir Medical Center /ID# 257626, Ẕerifin
MD Anderson Cancer Center /ID# 253713, Houston
Universitaetsklinikum Ulm /ID# 263148, Ulm
City of Hope /ID# 253904, Duarte
Hadassah Medical Center-Hebrew University /ID# 254721, Jerusalem
City of Hope Orange County Lennar Foundation Cancer Center /ID# 267158, Irvine
The Chaim Sheba Medical Center /ID# 254383, Ramat Gan
Atrium Health /ID# 265136, Charlotte
Duke Cancer Center /ID# 258707, Durham
Universitaetsklinikum Halle (Saale) /ID# 263299, Halle
Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 263062, Perugia
Lead Sponsor
AbbVie
INDUSTRY